While duplex ultrasound is the primary imaging tool for evaluating the venous system, blood tests play an important complementary role in the diagnosis and management of venous disease — particularly in patients with unexplained or recurrent deep vein thrombosis or pulmonary embolism. Understanding which blood tests are relevant to venous disease, what they measure, and how their results influence management helps patients engage more meaningfully with the diagnostic process.
D-dimer — a breakdown product of fibrin, the structural protein of blood clots — is the most widely used blood test in the initial evaluation of suspected DVT or pulmonary embolism. When clot is present and actively breaking down, D-dimer levels are elevated in the bloodstream. A negative D-dimer result in a patient with low clinical suspicion for DVT effectively excludes the diagnosis without the need for imaging, providing a safe and efficient rule-out strategy. However, D-dimer is non-specific — it is elevated in many conditions including infection, pregnancy, surgery, and cancer — meaning that a positive result requires imaging confirmation.
Thrombophilia testing — the assessment of inherited or acquired tendencies toward excessive clot formation — is indicated in specific clinical scenarios where identifying a clotting disorder would meaningfully change management. Common tests in this panel include Factor V Leiden mutation, prothrombin gene mutation, protein C and protein S activity, antithrombin levels, and antiphospholipid antibody syndrome screening. These tests are most informative in patients with unprovoked DVT, DVT at a young age, recurrent thrombotic events, or strong family history of clotting disorders.
The timing of thrombophilia testing relative to anticoagulation therapy is an important practical consideration. Many of the natural anticoagulant protein levels — protein C, protein S, and antithrombin — are reduced by anticoagulant therapy and by the acute thrombotic event itself. Testing performed during anticoagulation or within the immediate post-thrombotic period may produce falsely abnormal results. Where possible, definitive thrombophilia testing is deferred until anticoagulation has been completed and a suitable interval has elapsed.
Complete blood count, kidney function, liver function, and thyroid function tests provide information about systemic conditions that may contribute to or be caused by venous disease. Cancer screening — which may be triggered by an unexplained first DVT, particularly in older patients — involves a range of tests depending on the patient’s age, sex, and specific clinical features. The rationale for cancer screening in unexplained DVT is that occult malignancy is a recognized precipitant of thrombosis, and early identification of the underlying cancer may be lifesaving.